Associate Professor Karin Borges studied Biology at the University of Freiburg in Germany and obtained a PhD in Neurobiology from Heidelberg University. She continued her education as a postdoctoral fellow at the Department of Pharmacology at Emory University studying the regulation of transcription of the glutamate receptor subunits.
Since 2001, she has been interested in the morphological and functional changes involved in the development of epilepsy as an instructor at Emory University, then as Assistant Professor at Texas Tech University and since 2009 at the University of Queensland. Her long-term goal is to find new treatments for neurological disorders, including metabolic and anti-inflammatory approaches. To this end she has been receiving several grants from the Australian government, US philanthropic foundations and the pharmaceutical industry. These grants fund the work in the laboratory, in which five PhD students have graduated. Also the funds have allowed her to take her discovery of new anti-epileptic metabolic treatment into three clinical trials in Australia, which Dr. Borges has supervised.